Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: ADCY9 genetic variants and cardiovascular outcomes with evacetrapib in patients with high-risk vascular disease: a nested case-control study
Author: Nissen, S.
Pillai, S.
Nicholls, S.
Wolski, K.
Riesmeyer, J.
Weerakkody, G.
Foster, W.
McErlean, E.
Li, L.
Bhatnagar, P.
Ruotolo, G.
Lincoff, A.
Citation: JAMA Cardiology, 2018; 3(5):401-408
Publisher: American Medical Association
Issue Date: 2018
ISSN: 2380-6583
Statement of
Steven E. Nissen, Sreekumar G. Pillai, Stephen J. Nicholls, KathyWolski, Jeffrey S. Riesmeyer, Govinda J.Weerakkody, WendraM. Foster, Ellen McErlean, Lin Li, Pallav Bhatnagar, Giacomo Ruotolo, A. Michael Lincoff
Abstract: A pharmacogenetic analysis of dalcetrapib, a cholesteryl ester transfer protein inhibitor, reported an association between a single-nucleotide polymorphism (SNP) in the ADCY9 gene (rs1967309) and reduction in major adverse cardiovascular events despite a neutral result for the overall trial.To determine whether the association between the SNP in the ADCY9 gene and a reduction in major adverse cardiovascular events could be replicated for another cholesteryl ester transfer protein inhibitor, evacetrapib, in patients with high-risk vascular disease.A nested case-control study examining the rs1967309 SNP in 1427 cases and 1532 matched controls selected from the 12 092-patient Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High Risk for Vascular Outcomes (ACCELERATE) trial, a randomized, double-blind, placebo-controlled phase 3 trial conducted in patients with high-risk vascular disease randomized from October 2012 through December 2013. The genotyping was conducted from January 2017 to March 2017, and the data analyses were conducted from July 2017 to November 2017.Evacetrapib, 130 mg, or matching placebo.The primary analyses used a conditional logistic regression model to assess the odds ratio (OR) for major adverse cardiovascular events for evacetrapib compared with placebo for each genotype. The basic model included adjustment for age, sex, and the top 5 principal components. An additional model included cardiovascular risk factors to adjust for potential bias in selecting control patients. The primary major adverse cardiovascular event end point was the composite of death from cardiovascular causes, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina.For patients with the AA genotype reported to demonstrate a beneficial effect from dalcetrapib, the OR for evacetrapib compared with placebo was 0.88 (95% CI, 0.69-1.12). For patients with the AG genotype, the OR was 1.04 (95% CI, 0.90-1.21). For patients with the GG genotype reported to show evidence for a harmful effect from dalcetrapib, the OR for evacetrapib was 1.18 (95% CI, 0.98-1.41). The interaction P value among the 3 genotypes was P = .17 and the trend P value was P = .06. When adjusted for cardiovascular risk factors, the OR for evacetrapib was 0.93 (95% CI, 0.73-1.19) for the AA genotype, 1.05 (95% CI, 0.91-1.22) for the AG genotype, and 1.02 (95% CI 0.85-1.24) for the GG genotype; interaction P = .71 and trend P = .59.Pharmacogenetic analysis did not show a significant association between the ADCY9 SNP (rs1967309) and cardiovascular benefit or harm for the cholesteryl ester transfer protein inhibitor evacetrapib.
Keywords: Humans
Cardiovascular Diseases
Anticholesteremic Agents
Treatment Outcome
Risk Factors
Case-Control Studies
Polymorphism, Single Nucleotide
Cholesterol Ester Transfer Proteins
Adenylyl Cyclases
Rights: © 2018 American Medical Association. All rights reserved.
DOI: 10.1001/jamacardio.2018.0569
Published version:
Appears in Collections:Aurora harvest 8
Genetics publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.